The abstract is read at the publisher; the summary is JClub's.
Dexrazoxane preserves left ventricular systolic function after doxorubicin in 895 childhood cancer patients, with a z-score difference of 0.4 versus no dexrazoxane.
- Why it matters: Prior small studies suggested cardioprotection, but it was unclear whether the benefit persists in larger cohorts over time and how it might affect cardiomyopathy screening practices.
- What they did: Echocardiographic data from Children's Oncology Group protocols P9404, P9425, P9426, P9754, and Dana Farber Cancer Institute 95-01 were analyzed using generalized estimating equations and Cox models, adjusting for key treatment and patient factors.
- The result: Dexrazoxane was linked to lower hazards of reduced LV function at 1 year (0.58) and 5 years (0.54) postdiagnosis, and it reduced high-risk incidence from 40 to 21.8 events per 1,000 person-years (P = .001).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.